resolian.com valid
Resolian: Resolian is a specialist bioanalytical, biomarker and analytical sciences CRO supporting drug development with labs in USA, UK, Australia and China. One partner, one quality standard, four c
- Authority
- 47 reach 5 · trust 10 · quality 17 · freshness 15
- Tier
- listed
- llms.txt
- https://resolian.com/llms.txt
- Sections
- 5
- Links
- 130
- Size
- 34047 bytes
- Popularity rank
- #834824
- Registered
- 2023-02-07
- Country
- — Publisher location unknown; CDN address excluded
- Country evidence
- No published address evidence collected yet
- For agents
- Documentation: developer or product docs worth reading, nothing to call
- First seen
- 2026-10-19T10:45:04.199Z
- Last checked
- 2026-10-21T17:51:48.919Z
- Badge
Their llms.txt
The beginning of the file, from our validated copy saved 2026-10-21T17:51:38.689Z. Cached copy · Source on resolian.com
Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.
# Resolian: Resolian is a specialist bioanalytical, biomarker and analytical sciences CRO supporting drug development with labs in USA, UK, Australia and China. One partner, one quality standard, four continents.
## Sitemaps
[XML Sitemap](https://www.resolian.com/sitemap_index.xml): Includes all crawlable and indexable pages.
## Posts
- [Seeing What Immunoassays Can’t: An Ultra-Sensitive Nano-LC-MS/MS Platform for STAT6 Quantitation](https://www.resolian.com/resources/seeing-what-immunoassays-cant-an-ultra-sensitive-nano-lc-ms-ms-platform-for-stat6-quantitation/): Resolian developed a hybrid immunocapture nano-LC-MS/MS assay to quantify STAT6, a translational biomarker for RNA-degrading therapeutics, across human tissue types.
- [Simple by Design: A Validated 2-in-1 Assay for Acalabrutinib and Its Active Metabolite ACP-5862](https://www.resolian.com/resources/simple-by-design-a-validated-2-in-1-assay-for-acalabrutinib-and-its-active-metabolite-acp-5862/): Resolian developed and validated a simple, high-throughput HPLC-MS/MS method for simultaneous quantitation of acalabrutinib and its active metabolite ACP-5862 in human plasma, achieving an LLOQ of 1.00 ng/mL with a 20-minute extraction and no carryover.
- [A New Sensitivity Benchmark: Ultra-Sensitive Hybrid LC-MS/MS for siRNA Quantitation in Human Plasma](https://www.resolian.com/resources/a-new-sensitivity-benchmark-ultra-sensitive-hybrid-lc-ms-ms-for-sirna-quantitation-in-human-plasma/): Resolian developed the first hybrid LC-MS/MS method to achieve 50 pg/mL sensitivity for a duplex siRNA and its N-1 metabolite in human plasma, setting a new benchmark for regulated siRNA bioanalysis.
- [Strategies for ADC Bioanalysis: Building for Complexity, Designing for the Future](https://www.resolian.com/resources/strategies-for-adc-bioanalysis-building-for-complexity-designing-for-the-future/): Resolian's Andy Xue on what makes ADC bioanalysis uniquely demanding, and how the team builds scalable, drug-tolerant methods across ADCs, PDCs, and AOCs.
- [LC-MS for Protein Biomarkers: Precision Where Immunoassays Fall Short](https://www.resolian.com/resources/lc-ms-for-protein-biomarkers-precision-where-immunoassays-fall-short/): Resolian's Ashley Phillips on why LC-MS outperforms immunoassays for protein biomarkers, from isoform differentiation to drug-tolerant assay design.
- [Faster, Simpler Oligonucleotide Quantitation: An Extraction-Free qPCR Workflow for Tissue and Plasma](https://www.resolian.com/resources/faster-simpler-oligonucleotide-quantitation-an-extraction-free-qpcr-workflow-for-tissue-and-plasma/): Resolian developed an extraction-free, direct-to-qPCR workflow that accurately quantifies therapeutic oligonucleotides across plasma and multiple tissue types using a single calibration curve, reducing hands-on time and cost without compromising performance.
- [One Pi
…Machine-readable: GET /v1/resolve?q=resolian.com · GET /v1/domain/resolian.com · this page as Accept: application/json or text/markdown · MCP lookup_domain
Automatically discovered from public files. Inclusion does not imply endorsement or publisher participation.
Own or manage this website?
If you own or manage resolian.com, you can update its listing and review file health, discovery activity and score history.
Manage this listing — optional
What verification unlocks
See how your site is discovered—and control what agents see.
- See your website in the map
Review your indexed topics, nearby publishers sharing headings, measured listing exposure and map snapshots in a private report for your website.
- Control what agents see
Edit your listing description, tags, public contact details and additional llms.txt paths. Publish your terms for automated access, attribution and pricing.
- Make your profile eligible for search
A valid, listed, unblocked, verified profile can appear in our publisher sitemap and become eligible for search-engine visibility. Search engines decide what to index and rank.
- Appear in our llms-full.txt
Eligible verified publishers are listed by name, with their file links and summaries, in the service overview agents can read.
Free. No account registration, backlink or payment required. Public discovery remains available without verification.
Let your coding agent verify it
If your coding agent is authorized to manage this website, paste these instructions into it.
Claim my listing on Agent Web Map for resolian.com:
1. POST https://agentwebmap.com/v1/sites/resolian.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://resolian.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/resolian.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/resolian.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verifyCorrections or removal requests: contact the directory.